Table 1.
Clinical trials investigating immunotherapeutic agents in localized gastroesophageal adenocarcinoma.
| Trial Name | National Clinical Trial Number | Phase | Immunotherapy | CHT-Backbone | N | Setting | Ethnicity | Primary Endpoint | Recruitment Status |
|---|---|---|---|---|---|---|---|---|---|
| DANTE | NCT03421288 | II | Atezolizumab | FLOT | 295 | Peri-OP | Caucasian | PFS/DFS | Active, not recruiting |
| KEYNOTE-585 | NCT03221426 | III | Pembrolizumab | FLOT/CP/FP | 800 | Peri-OP | Caucasian/Asian | OS/EFS/pCR | Active, not recruiting |
| MATTERHORN | NCT04592913 | III | Durvalumab | FLOT | 900 | Peri-OP | Caucasian/Asian | EFS | Active, not recruiting |
| n.a. | NCT02918162 | II | Pembrolizumab | CP | 36 | Peri-OP | Caucasian | pCR | Completed |
| EORTC-VESTIGE | NCT03443856 | II | Nivolumab/Ipilimumab | mono | 240 | Adjuvant | Caucasian | DFS | Active, not recruiting |
| ATTRACTION-05 | NCT03006705 | III | Nivolumab | S1/CP | 700 | Adjuvant | Asian | RFS | Active, not recruiting |
| NEONIPIGA | NCT04006262 | II | Nivolumab/Ipilimumab | mono | 32 | Peri-OP | Caucasian | pCR | Recruiting |
| INFINITY | NCT04817826 | II | Durvalumab/Tremelimumab | mono | 31 | Neoadj/Def | Caucasian | pCR/CRR | Recruiting |
| IMHOTEP | NCT04795661 | II | Pembrolizumab | mono | 120 | Peri-OP | Caucasian | pCR | Recruiting |
Abbreviations: N = number of patients; FP = fluoropyrimidine + platin; CP = capecitabine + platin; peri-OP = perioperative; neoadj = neoadjuvant; def = definitive; pCR = pathological complete remission; PFS = progression-free survival; DFS = disease-free survival; OS = overall survival, EFS = event-free survival; RFS = recurrence-free survival; CRR = complete response rate, n.a. = not available. Recruitment status according to clinicaltrials.gov (accessed on 13 December 2022).